Skip to content
en|ru

Investment & development roadmap

Where Safira Pharma goes next

Six initiatives define our next stage: own trademarks, expanded manufacturing, localization, joint ventures, infrastructure investment and biotechnology. Each one deepens what we can deliver for partners, health authorities and patients.

Roadmap

Six initiatives, one direction

Every initiative below has an owner, a horizon and defined success criteria. The status reflects our current investment stage — from active development to early evaluation.

In developmentPlannedUnder evaluation
  1. 2026In development

    Private Label Portfolio

    A portfolio of Safira-owned trademarks in high-demand generics and consumer health categories. We select molecules by regional epidemiology and tender demand, place production at GMP-certified plants and register every product in our own name.

    First launches are prepared for Turkmenistan and Uzbekistan, with rollout across the wider region to follow.

    • Registration certificates and trademarks held by Safira
    • Margin structure independent of licensor terms
    • A portfolio shaped by regional tender demand
  2. 2026–2027In development

    Contract Manufacturing Scale-Up

    Expansion of our GMP contract-manufacturing network in India and beyond: additional dosage forms, larger batch capacity and full technology-transfer capability. The goal is to produce for our own portfolio and for partners at predictable cost and consistent quality.

    • A wider network of audited GMP sites
    • Technology transfer for partner molecules
    • Capacity reserved for regional tender volumes
  3. 2027Planned

    Production Localization

    Local packaging — and, in later phases, full manufacturing — in Central Asia, aligned with government localization incentive programmes. Local production shortens supply chains, earns preferential treatment in public procurement and creates skilled jobs in the region.

    • Secondary packaging lines in priority markets
    • Preferential status in government tenders
    • Compliance with national localization programmes
  4. 2027–2028Planned

    Joint Ventures

    Joint ventures with international manufacturers to build regional plants and shared distribution infrastructure. Safira contributes regulatory access, government relations and market knowledge; partners bring technology and product pipelines.

    • Shared production assets in the region
    • Combined distribution reach across five markets
    • Long-term supply agreements with health authorities
  5. 2028Under evaluation

    Pharmaceutical Investments

    Co-investment in the infrastructure the regional pharmaceutical market still lacks: GDP-compliant warehousing, cold-chain logistics and independent quality-control laboratories. Each asset is assessed jointly with financial and industry partners against strict compliance criteria.

    • GDP-grade warehouse capacity in key hubs
    • Unbroken cold chain for biologics and vaccines
    • Independent QC laboratory capability
  6. ExplorationUnder evaluation

    Biotechnology Programmes

    Registration pathways for biologics across Central Asian jurisdictions, and partnerships in plasma-derived medicines and biosimilars. Building on our work with BioPharma Plasma, we are mapping how modern biotherapies can reach the region’s patients sooner.

    • Defined biologics registration pathways per market
    • Partnerships in plasma products and biosimilars
    • A pharmacovigilance framework for biotherapies

Horizons reflect current planning and are reviewed as regulatory and market conditions evolve.

Partnership & investment

Build the next stage with us

Manufacturer, investor or technology partner — tell us where you see the fit. We respond with a concrete proposal, not a brochure.

Discuss a partnership or investmentExplore Services
Contact Us